The Effect of Mobile Application-Assisted Nursing Services on Symptom Control in Breast Cancer Patients

NCT ID: NCT07200791

Last Updated: 2025-12-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

74 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-31

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Breast cancer is the most common type of cancer in women, accounting for approximately one-quarter of all female cancers in Turkey. Chemotherapy is widely used in treatment, but it also affects healthy cells, leading to numerous side effects such as fatigue, nausea, hair loss, sleep problems, and skin and nail changes. These side effects complicate symptom management and negatively impact patients' self-efficacy and quality of life.

Mobile health applications allow patients to track their symptoms, communicate with healthcare professionals, and implement recommended non-pharmacological methods. Literature demonstrates that these applications reduce symptoms, improve quality of life, and enhance self-efficacy.

This research is a randomized controlled experimental trial designed to evaluate the effect of mobile app-assisted nursing services on symptom management in women diagnosed with breast cancer and undergoing chemotherapy. The research will be conducted in the chemotherapy unit of a training and research hospital in Istanbul.

The study will consist of two groups: an intervention group and a control group. Randomization will be conducted using a computer-assisted method (random.org). Based on the power analysis, 74 patients will be included in the sample for 85% power at a 95% confidence interval, a significance level of p\<0.05, and a medium effect size.

Inclusion criteria include individuals aged 18 years and older, female, diagnosed with breast cancer, undergoing the 4AC-12 Paclitaxel protocol, owning and using a smartphone, and consenting to participate in the study. Exclusion criteria include patients with cardiac problems, liver or kidney failure, inability to use the mobile app, or providing incomplete data.

Study data will be collected online via a mobile app. The results of the study will demonstrate the effectiveness of mobile health apps in symptom management, increasing self-efficacy, and improving quality of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Breast cancer is the most prevalent malignancy among women in Türkiye, representing approximately one-fourth of all female cancers. Chemotherapy remains a cornerstone of treatment but often causes multiple physical and psychological side effects. Common symptoms such as fatigue, nausea, alopecia, sleep disturbances, skin and nail changes, and emotional stress complicate self-management and reduce quality of life.

Mobile health (mHealth) applications offer an innovative approach for patients to self-monitor symptoms, access educational materials, and communicate with healthcare professionals in real time. Recent evidence indicates that mHealth-based nursing interventions can improve symptom control, enhance self-efficacy, and support adherence to non-pharmacological management strategies during chemotherapy.

This randomized controlled experimental study aims to evaluate the effectiveness of a mobile application-assisted nursing intervention on symptom management, self-efficacy, and quality of life among women diagnosed with breast cancer and receiving chemotherapy. The study will be conducted in the chemotherapy unit of a training and research hospital in Istanbul, Türkiye.

A total of 74 participants will be randomly assigned to either the intervention or control group using a computer-generated randomization system (random.org). The intervention group will receive routine nursing care plus access to a specifically designed mobile application developed for this study.

The mobile application includes:

A symptom monitoring module for daily recording of symptom severity using the Edmonton Symptom Assessment Scale (VAS 0-10).

Educational and behavioral guidance on fatigue management, nutrition, sleep hygiene, and coping with nausea.

Interactive features providing daily reminders, self-care tips, and remote nursing follow-up capabilities.

Participants in the intervention group will actively use the mobile application throughout their chemotherapy protocol (4AC-12 Paclitaxel regimen, approximately 16 weeks). The control group will receive standard nursing care only.

Inclusion Criteria

Women aged 18 years or older

Diagnosed with breast cancer

Undergoing the 4AC-12 Paclitaxel chemotherapy protocol

Literate and able to communicate effectively

Owning a smartphone

Able to use a smartphone and mobile application

Voluntarily consenting to participate in the study

Completing all required data collection forms

Exclusion Criteria

Individuals with cardiac disease

Individuals with liver or renal failure

Individuals unable to use a smartphone or the mobile application

Individuals who withdraw from the study at any stage

Participants with incomplete or missing data for any reason

Outcome Measures

Primary Outcome:

Change in symptom severity measured by the Edmonton Symptom Assessment Scale (VAS 0-10) at baseline, mid-intervention, and post-intervention.

Secondary Outcomes:

Change in self-efficacy level, measured using the Self-Efficacy Scale.

Change in quality of life, measured by the EORTC QLQ-C30 or Quality of Life Scale at three time points (T0, T1, T2).

Study data will be collected electronically through the mobile application and analyzed using appropriate statistical methods (descriptive statistics, paired and independent t-tests, and regression analysis).

This study is expected to provide scientific evidence for the use of mobile health technologies as supportive nursing tools in oncology care, demonstrating their potential to enhance symptom management, strengthen self-efficacy, and improve patients' quality of life during chemotherapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Symptom Management Quality of Life

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

experimental arm(ıntervention group): Mobile application and usual care

Participants in this group will receive routine nursing care and the standard hospital educational booklet. In addition, they will use a mobile application developed to support chemotherapy-related symptom management. The app includes modules for symptom tracking, short educational videos (approx. 2 minutes each), and written/visual brochures. Before use, participants will be trained on installation and navigation. They can also contact a nurse or researcher via the app for questions.

Group Type EXPERIMENTAL

Mobile Application

Intervention Type BEHAVIORAL

Participants in this group will receive routine nursing care and the standard hospital educational booklet. In addition, they will use a mobile application developed to support chemotherapy-related symptom management. The app includes modules for symptom tracking, short educational videos (approx. 2 minutes each), and written/visual brochures. Before use, participants will be trained on installation and navigation. They can also contact a nurse or researcher via the app for questions.

Control Arm: Usual Care Only

Participants in this group will receive routine nursing care and the standard hospital educational booklet. No additional intervention will be provided.

Group Type ACTIVE_COMPARATOR

Usual Care Only

Intervention Type BEHAVIORAL

Participants in this group will receive routine nursing care and the standard hospital educational booklet. No additional intervention will be provided.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mobile Application

Participants in this group will receive routine nursing care and the standard hospital educational booklet. In addition, they will use a mobile application developed to support chemotherapy-related symptom management. The app includes modules for symptom tracking, short educational videos (approx. 2 minutes each), and written/visual brochures. Before use, participants will be trained on installation and navigation. They can also contact a nurse or researcher via the app for questions.

Intervention Type BEHAVIORAL

Usual Care Only

Participants in this group will receive routine nursing care and the standard hospital educational booklet. No additional intervention will be provided.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 yaş ve üzerinde olan,
* Çalışmaya katılmayı kabul eden,
* Meme kanseri tanısı alan kadınlar,
* 4AC-12 Paklitaksel tedavi protokolü uygulana,
* Okuma yazma bilen ve iletişim problemi olmayan,
* Akıllı telefonu olan bireyler
* Akıllı telefonu kullanabilen bireyler
* Verileri eksiksiz olarak dolduran bireyler

Exclusion Criteria

* Kardiyak problemi olan bireyler
* Karaciğer ve böbrek yetmezliği olan bireyler
* Mobil uygulama kullanamayan bireyler
* Akıllı telefon kullanamayan bireyler
* Araştırmadan ayrılmak isteyen bireyler
* Araştırmada çeşitli sebeplerle eksik veri toplanan bireyler
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fenerbahce University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Demet SEMİZ

Lecturer

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Demet DEMET SEMİZ

Role: CONTACT

05457120188

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

82.2025fbu

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.